NovaBay Launches Avenova Product Bundles For Relief From Multifactorial Dry Eye Symptoms
NovaBay Launches Avenova Product Bundles For Relief From Multifactorial Dry Eye Symptoms
Approximately 16 million Americans suffer from dry eye disease with the U.S. market for dry eye treatment projected to reach $4.86 billion by 2030
大約有1600萬美國人患有乾眼病，預計到2030年，美國乾眼治療市場將達到48.6億美元
NovaBay Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduction of an expanded line of Avenova product bundles specifically designed to provide easy, affordable and effective solutions for individualized relief from dry eye symptoms. The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.
開發和商業化高質量眼部護理和傷口護理產品的公司NovaBay Pharmicals, Inc.（紐約證券交易所代碼：NBY）宣佈推出擴大的Avenova產品套裝系列，專門爲個性化緩解乾眼症狀提供簡單、實惠和有效的解決方案。新的Avenova產品組合與《Eyes on Eyecare 2024 Dry Eye Report》中調查的驗光師的研究結果一致，該報告對乾眼病的多因素性質進行了調查，並建議除人工淚液之外的個性化治療對於成功的治療可能很重要。
譯文內容由第三人軟體翻譯。